Melinta reports Phase III success for antibiotic
This article was originally published in Scrip
Connecticut-based Melinta Therapeutics says that a Phase III study of its lead product, the investigational fluoroquinalone antibiotic, delafloxacin IV has met its primary end point.
You may also be interested in...
The latest drug development news and highlights from our FDA Performance Tracker.
The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.
The R&D-based lobby group, Medicines Australia, has published a report calling for stakeholders across the Australian healthcare ecosystem to discuss how to “pragmatically address the evidence needs of the future.”